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Growth of sebaceous glands in the ears and flank organs of 
castrated male hamsters is dependent on androgen substitu- 
tion. Taking this for granted, a study was done to compare 
the effects of topical antiandrogenic treatment in vivo on the 
morphology and size of sebaceous glands with the concomi- 
tant changes in in vitro metabolism of 3H-testosterone. The 
role of dihydrotestosterone in sebaceous gland stimulation 
was thereby investigated. 
Topical treatment was carried out with the androgen an- 
tagonist 17a-propylmesterolone (PM), with 4-androsten-3- 
one-17j%carboxylic acid (17/I-C), and 17&N,N_diethylcar- 
bamoyl-4-methyl-4-aza-5a-androstan-3-one (4-MA), both 
described as specific 4-steroid-5a-reductase inhibitors, and 
with progesterone (PRO), which is an androgen receptor 
antagonist with 5cw-reductase inhibiting properties. 
Regrowth of sebaceous glands after castration and substi- 
tution with testosterone propionate or dihydrotestosterone 
could be inhibited by topical PM and PRO. This occurred 
irrespective of the influence on testosterone metabolism and 
irrespective of the mode of substitution. 4-MA, on the other 
hand, while exhibiting strong 5a-reductase inhibition in 
vitro, was ineffective in reducing sebaceous gland sizes in 
vivo. The compound 17/?-C was ineffective in every respect. 
In no case were systemic antiandrogenic effects on prostates 
and seminal vesicles observed. 
Our results support the view that the DHT formation rate 
has no regulatory function for growth of sebaceous glands in 
hamsters and that PM and PRO counteract the androgenic 
stimulus by their competitive antagonistic binding to the 
androgen receptor, but not by their influence on testosterone 
metabolism.] Invest Dermatol’92:769- 773, 2 989 
U 
p to now, the search for a topically active antiandro- 
genie agent for treatment of androgen mediated 
skin diseases such as seborrhoea and acne has been 
unsuccessful. All such trails have ended up with 
antiandrogens such as cyproterone acetate with a 
topical ineffectiveness coupled with the disadvantage of systemic 
“antiandrogenic” side effects, which are acceptable neither for men 
nor for unprotected fertile women [l]. 
One possible explanation for the disappointing results in this 
field is the lack of knowledge of the regulatory functions of andro- 
gens in sebaceous glands, and consequently of the required bio- 
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Andiol: 5a-androstane-3ar,l7/%diol 
Andion: 5a-androstane-3,17-dione 
17&C: androst-4-en-3-one-17@uboxylic acid 
DHT: 5wdihydrotestosterone 
Endion: 4-androstene-3,17-dione 
4-MA: 178-N,N-diethylcarbamoyl-4-methyl-4-aza-5-androst~-3- 
one 
PM: 17wpropylmesterolone 
PRO: progesterone 
T: testosterone 
TLC: thin-layer chromatography 
TP: testosterone propionate 
chemical mode of action. Because androgen receptors, as well as 
androgen-metabolizing enzymes, have been detected in human and 
hamster sebaceous glands [2-51, two main possibilities of antian- 
drogenic action can be imagined: a) blockade of the androgen recep- 
tor by a genuine androgen antagonist, or b) inhibition of DHT 
formation by a 5a-reductase inhibiting agent. 
Our experiments were designed to clarify the role of the two 
mechanisms in the male hamster ear and flank organ models [6,7] by 
in vivo topical application of compounds with different mecha- 
nisms of antiandrogenic activity. 
PM can be regarded as a pure corn etitive antagonist for the 
androgen receptor. It exhibits a high a B nity for receptors in ham- 
ster ear sebaceous glands and causes depletion of high-affinity cyto- 
plasmic androgen binding sites after topical application [8]. 
Two possible candidates for decreasing DHT formation, 4-MA 
and 17p-C, have been reported to inhibit 4-androstene-5a-reduc- 
tase in vitro and in vivo [9 - 111. They have no or at least a very low 
affinity for the androgen receptor. On the contrary, PRO is assumed 
to exert an antiandrogenic influence by virtue of a combination of 
competitive antagonistic and 5cu-reductase inhibiting properties 
[121. 
MATERIALS AND METHODS 
Chemicals la-methyl-l7cY-propyl-l7j%hydroxy-5a-androstan- 
3-one (17&propylmesterolone = PM, mol. wt. 346.6, SH 434), 
progesterone (PRO, mol. wt. 314.5), 4-androsten-3-one-I7/%car- 
boxylic acid (17p-C, mol. wt. 316.4), 17/?-N,N-diethylcarbamoyl- 
4-methyl-4-aza-5-androstan-3-one (4-MA, mol. wt. 388.6) were 
all synthesized in our laboratories (Fig 1). Chemicals were pur- 
chased from Merck, Darmstadt, FRG. 
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5548). The metabolites of 3H-testosterone were separated in dichlo- 
romethane-ethyl acetate-methanol (85-l 5-l), ascending, in the un- 
saturated chamber. The steroid metabolites were detected radiologi- 
cally with the aid of a TLC linear analyzer (Type LB 2832, 
Berthold/Wildbad, FRG). 
The counter results were evaluated by taking the total sum of the 
im 
dn 
ulses ofone track as 100% and calculating the percentages ofthe . . 
Using both TLC and gas chromatography with mass spectrome- 
in ivl; spots. try, we were able to identify 5a-dihydrotestosterone (DHT), 3a- 
androstanediol (Andiol), 4-androstenedione (Endion), 5cu-andro- 
stanedione (Andion), and androsterone as the principal metabolites 
of 3H-testosterone, but we did not repeat the GCMS procedure in 
each experiment. It was not possible to separate DHT from andros- 
terone in the TLC system employed. In a single experiment, we 
continued TLC in a second dimension using dichloromethane- 
diethvl ether (9 + I). reneatinz the nrocedure three times. follow- 
ing which it was pos$ibl; to dis&gui’sh androsterone from DHT on 
the plate. We could thus show that the changes in DHT spot radio- 
activitv are due to the variation of DHT and nossiblv are not com- 
Figure 1. The four potential antiandrogens applied topically in the hamster 
ear and flank organ models. 
Design There were two basic experiments both of which used 
castrated male Syrian Golden hamsters, body weight 80 - 100 g 
(Hoechst, Frankfurt). For the first experiment, 30 animals were 
randomly allocated to six treatment groups of five animals each. All 
groups but one were subcutaneously injected with 0.1 mg/d/ani- 
ma1 Testosterone propionate (TP). For the second experiment, 25 
animals were randomly allocated to five groups of five animals each. 
All groups were subcutaneously injected with 0.03 mg/d/animal 
dihydrotestosterone (DHT). The animals were castrated on day 
zero and the androgens were injected from day seven to day 28, 
except on Sunday. The androgens were dissolved in 0.1 ml 10% 
benzyl benzoate/castor oil. 
, I I 
pensated for by androsterone formation. 
The in vitro method provides constant incubation and extraction 
conditions with a 84% + 8.6% recovery rate of radioactivity and 
small standard deviations for detection of the individual metabo- 
lites. 3H-testosterone metabolism was not influenced by 3H-testos- 
terone concentrations between 3 X lop9 and 1 X IO-‘M and incu- 
bation times up to 90 min. 
Twice daily, 300 pg of the respective test substance dissolved in 
10 ~1 ethanol (96%) (in the case of 17/3-C: 100 pg in ethanol-ethyl- 
ene glycol-Ha0 = 60-30-10) was applied to the rostra1 area of the 
right ear and the shaved right flank organ. The topical treatment 
was also applied from day seven to day 28, except on Sunday. Con- 
trol groups were treated topically with ethanol alone. The animals 
were caged individually, observing a light-darkness cycle of 12 h, 
and fed with Altromin” and water ad libitum. On day 29, the ani- 
mals were killed with CO, and the seminal vesicles and prostates 
removed and weighed. The ears and flank organs were excised and 
prepared as described below. The flank organs were also weighed 
Histologic Examination A small section between the first and 
second cartilage ridges of each ear was fixed in formalin, and a 
3 X 7 mm sample was punched out of the center of this section and 
embedded in paraffin. The samples were sectioned (approximately 
3-5 pm thick) and stained with haematoxylin and eosin. Morpho- 
metric determinations were conducted with the aid of an image 
analyzer (Kontron MOP/AM-O1 system). The sebaceous gland 
areas (excluding the sebum secreta) were assessed in 5 consecutive 
visual fields of one typical section and the mean was computed. 
Statistics The reduction in flank organ weights and ear sebaceous 
gland areas is expressed as percent inhibition derived from the re- 
spective control groups. Ninety-five percent confidence limits were 
derived for the percentage scale [ 131. The variations in the individ- 
ual 3H-testosterone metabolites were compared with those in the 
controls by means of a Dunnett test [14]. 
RESULTS 
ination, a round specimen of the ear (7 mm diameter) was taken by 
after excision. 
punch distal to the second cartilage ridge, and the rostra1 part was 
3H-testosterone Metabolism (In Vitro) 
stripped from the underlying cartilage. The flank organs were cut 
off from the surrounding cutaneous tissue, the subcutaneous layers 
For biochemical exam- 
were removed, and four thin strips were sliced from the well-devel- 
oped center with a razor blade (total weight of the strips: approx 
10 mg). Immediately afterwards, the ear specimens and tissue sec- 
tions of the flank organs were incubated with (l,2,6,7)-3H-testos- 
terone (3 X lO_sM, 1.5 X IO6 cpm/tube, Amersham-Buchler). 
The incubation took place in 5-ml tablet tubes in 0.5 ml Minimum 
Essential Medium plus Earle’s Salts, pH 7.0 (Seromed, Cat. No. 
0323) with glucose (10V2M), penicillin (Hoechst, 1000 IU/ml), 
and streptomycin (Horm Chemie, 100 pg/ml). The samples were 
exposed for 45 set to O,/CO, (95 : 5), and sealed and incubated for 
I h in a shaking water bath at 37°C. The reaction was stopped by 
addition of 2 ml chloroform-methanol (2 + 1) and the 3H-testos- 
terone metabolites were extracted by agitation on the supermixer 
for 1 min. The extract was dried overnight at 4°C over MgS04. 
Thin-layer Chromatography A mixture of authentic steroids 
(20 pg of each known metabolite) was added to 150 ~1 of each 
extract, and the concentrated sample applied in a punctiform pattern 
to a thin-layer plate (HPTLC aluminium foils, Merck Cat. No. 
atrophy is not documented in this study, but the regrowth to normal 
During the 7-d period of androgen deprivation after castration, the 
values, induced by three-week androgen substitution, was assessed 
by flank organ weight and ear sebaceous gland area determinations. 
sebaceous glands shrink to a minimal size. This sebaceous gland 
Because the flank organs consist almost entirely of sebaceous 
glands, their weights can be used to indicate the status of sebaceous 
gland development. On the other hand, the ear comprises dermal 
and epidermal compartments in the skin as well as sebaceous glands. 
Therefore, the sebaceous gland sizes have to be determined histo- 
logically. For the same reason, 3H-testosterone metabolism of the 
flank organs can be regarded as a reflection of the metabolic activity 
of pure sebaceous glands, while the metabolic activity of the ear 
specimen comprises the metabolic activity of the whole skin. The 
implications of this will be discussed later. 
Morphologic Criteria of Androgen Target Tissues The de- 
gree to which sebaceous gland regeneration was impaired by topical 
antiandrogen treatment varied. In the ears, statistically significant 
reductions of sebaceous glands were observed only with PM and 
PRO, although there are also slight reductions in the DHT-stimu- 
lated groups treated with 17p-C or 4-MA. These latter effects, 
however, cannot be attributed to any Sa-reductase inhibiting prop- 
erties of 17p-C and 4-MA because such properties should be inef- 
fective in DHT-substituted animals (Fig 2~). The flank organs dis- 
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play a lower tendency to be impaired by appiied antiandrogens than 
the sebaceous glands of the ears. Again, only the changes induced by 
PM and PRO were statistically significant (Fig 2b). The absence of 
systemic side effects according to prostate and seminal vesicle 
weights (not shown) suggests a local mechanism of action. The 
weights of the contralateral flank organs were not influenced either. 
‘H-testosterone Metabolism In Vitro The changes in testoster- 
one metabolism induced by topical antiandrogen treatment were 
investigated by incubating the sebaceous gland-containing speci- 
men with 3H-testosterone in vitro. The possible metabolic path- 
ways of testosterone are depicted in Fig 3. 
The percentages of radioactivity for each metabolite are shown in 
Figs 4 and 5. In the ears there is a large increase in DHT formation 
caused by PM and PRO and a concomitant decrease of androstane- 
dione. Quite a similar observation was made in the control group 
without androgen substitution. The opposite effect can be observed 
in principle in the flank organs, but this is not always significant. 
The DHT-substituted groups exhibit the same alterations as the 
TP-stimulated groups. 
There is also fundamentally decreased formation of 5a-reduced 
steroids caused by 4-MA (Table I), which was always accom anied 
by an increase in androstenedione. These are the expected e t9 ects of 
a specific 5cY-reductase inhibitor. PRO only exerted a significant 
5a-reductase inhibiting influence in the flank organs but not in the 
ears. The decrease in 5a-reduced metabolites correlates well with a 
decrease in testosterone utilization. This is most obvious in the 
4-MA-treated and castrated non-substituted groups. 17~~C dis- 
played no Scu-reductase inhibiting properties under these experi- 
mental conditions. The alterations observed in the ears under topi- 
cal treatment were not observed in the respective contralateral ears 
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Figure 2. Changes in sebaceous gland areas in hamster ears (A) and in flank 
organ weights (B) following topical antiandrogens. Castrated male hamsters 
were substituted with TP or DHT over 3 weeks and concurrently treated 
topically with antiandrogens (600 pg PM, PRO and 4-MA/site/day and 
200 pg 17P-C/site/day) or received only the vehicle. The percent alter- 
ations of sebaceous gland areas in the histologic sections of the ears (A) and 
of the flank organ weights (B) in terms of the control values of topically 
applied vehicle are shown. solid circle: TP-substitution s.c.; open circle: DHT- 
substitution s.c.; asterisk: significant alteration with (Y = 5% (for statistics see 
methods). 
Figure 3. Pathways of testosterone metabolism in sebaceous glands of the 
hamster. The enzymes involved are 17/I-hydroxysteroid dehydrogenase 
(17P-HSD), 4-androstene-5&-reductase (ticy-Red), and 3a-hydroxysteroid 
dehydrogenase (3~HSD). 
(not shown), whose metabolism strongly resembled that in the con- 
trol groups. This again suggests the topical specificity of all the 
compounds applied. 
DISCUSSION 
We intended to clarify the mechanism of action of PM and the role 
of DHT in sebaceous gland stimulation of the hamster ear skin and 
flank organ. We obtained several lines of evidence. 
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Figure 4. Changes in 3H-testosterone metabolites produced in hamster ears 
following topical antiandrogens. The animals were treated as described in 
Fig 2. The skin specimens were incubated in vitro for 1 h in a 3H-testoster- 
one-containing medium immediately after the animals had been killed. A: 
TP-substituted groups; B: DHT-substituted groups. The bars represent the 
Ecentages of each sH-testosterone metabolite on the thin-layer tracks 
(X zt SD, whole track = 100%). Black bars: Sa-reduced steroids; hatckea’boc 
Endion. 1: androstanediol; 2: dihydrotestosterone; 3: androstenedione; 4: 
androstanedione; 5: testosterone residue. The controls were systemically 
substituted with TP or DHT, while the vehicle only was applied to the ears 
and flank organs. Asterisk: significant for control with CY = 5%, Dunnett’s 
test. 
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. :c tr,l,um labelled androger. 
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4-MA vehicle vehicle 
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explained by the reduction of 17/?-hydroxysteroid dehydrogenase 
(17-HSD) activity. Th is activity is indeed the only one which corre- 
lates at all well with sebaceous gland size in the ear. It is an open 
question as to whether this enzyme declines passively with atrophy 
of the sebaceous glands, or whether it is androgen-dependent and 
declines because of androgen deprivation. Still, we cannot decide in 
which compartment of the skin it may be preferentially localized. 
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Figure 5. Changes in 3H-testosterone metabolites produced in flank organs 
following topical antiandrogens (see Fig 4 legend). 
1) In the ear, PM, PRO, and the omission of androgen substitu- 
tion considerably decrease sebaceous gland sizes, but the overall 
5a-reductase activity decreases only marginally and also 3H-testos- 
terone turnover rates remain high. Consequently, one may con- 
clude that the enzyme is highly active in the surrounding dermal 
and epidermal tissues. Therefore, 5a-reductase in the sebaceous 
gland, per se, might well have been low but masked by the high 
activity in other tissues. This conclusion ap 
activity of 5cu-reductase for human skin broblasts and keratino- F 
ars likely because high 
cytes has been reported [ 15,161. Another explanation would be that 
the Sa-reductase is induced by androgen deprivation, as proposed by 
Takayasu and Adachi [17]. 
The increase in DHT and the concomitant decrease of androstan- 
edione (the principal androgen in the hamster ear) in the ears can be 
Table I. Percentages of 5a-Reduced 5H-testosterone 
Metabolites Produced In Vitro After In Vivo Topical 
Treatment of Ears and Flank Organs 
Group 
Topical Androgen 
Treatment Substitution 
1 PM 
2 PRO 
3 178-C 
4 4-MA 
5 ethanol 
6 ethanol 
TP 39.7 f 4.1 31.9 f 7.1 
DHT 39.2 f 3.9 33.6 f 3.1 
TP 35.8 f 2.2 21.3 + 1.6’ 
DHT 43.8 z!z 4.3 21.2 z!z 4.5” 
TP 44.9 + 4.8 35.9 + 4.9 
DHT 51.2 + 3.2 36.2 z!z 4.9 
TP 19.3 + 5.3” 11.9 + 4.2” 
DHT 29.8 k 4.7* 7.4 f 2.5’ 
TP 42.2 f 2.5 33.9 + 8.7 
DHT 47.1 +- 4.9 29.4 f 6.3 
oil 31.7 f 2.9 7.1 + 3.2a 
Scu-Reduced Steroids 
(DHT + An&on + Andiol) 
%(X&SD) 
Ear Flank Organ 
* significantly different from control (group 5). 
OL = l%, Dunnett’s test. 
2) In the flank organ different effects are observed. Again, PM 
and PRO reduce gland sizes but only PRO acts as a Sa-reductase 
inhibitor, thereby decreasing DHT and increasing androstenedione 
formation, while PM exerts almost no significant metabolic effects. 
The flank organs consist of compact, pure sebaceous glands. The 
lower efficiency of PM and PRO at this site may be explained by the 
long diffusion path of topical agents to the deeper layers of the 
gland. Accordingly, the metabolic pattern is only moderately in- 
fluenced. 
3) From the foregoing, it is obvious that similar effects of PM and 
PRO on morphologic parameters in the ears as well as in the flank 
organs do not correlate with lower 5a-reductase activity or a respec- 
tively lower DHT level. On the other hand, PRO proved in the 
flank organ to be a weak Sa-reductase inhibitor. Under both com- 
pounds, however, DHT levels increase in the ear. Their effectivity 
can therefore only be explained by competition for androgen recep- 
tor binding sites. The fact that PM and PRO are equally effective in 
TP- as well as in DHT-substituted groups also demonstrates their 
antagonistic working mechanism. 
4) The 5a-reductase inhibitor 4-MA has clear-cut and expected 
effects on testosterone metabolism, but there is not even a slight 
correlation with sebaceous gland sizes in the hamster. The metabo- 
lite spectrum of the still fully developed flank organ even resembles 
that of the very small one in castrated, vehicle-treated controls. The 
slight inhibitory effect on ear sebaceous glands in the DHT-substi- 
tuted group should not be overinterpreted. 
5) The compound 17p-C has no effect on gland sizes or metabo- 
lite spectrum. Again, in the light of the other groups, the inhibitory 
effect on ear sebaceous glands under DHT substitution does not 
appear to be biologically relevant. However, it must be borne in 
mind that the applied dose of this compound is one-third of that for 
the others. 
6) The mechanism of response of the ear sebaceous glands and the 
flank organs are different. Whatever their explanation, the differ- 
ences in androgen metabolism between the two structures reinforce 
the conclusions from the morphologic studies. 
The literature still presents a heterogeneous picture of antiandro- 
genie properties of some of the above-mentioned compounds. Con- 
flicting results concerning I7p-C are reported by Voigt and Hsia 
[l l] and Luderschmidt and Plewig [18], the latter supporting our 
results. As regards topical PRO, we contradict Girard and Barbier 
[19], who could not show an effect under DHT substitution, but we 
agree with Foreman et al [20]. Distinct differences in the experi- 
mental design may be an explanation for this disagreement. On the 
other hand, there is no doubt about the influence on the metabolic 
profile exerted by 4-MA. Its strong 5a-reductase inhibition ob- 
served in this study can be regarded as proof of the validity of our test 
system. 
The effectiveness of PM can be deduced from its competitive 
antiandrogenic properties. This characteristic has been widely eval- 
uated by ourselves (classical antiandrogen studies in vivo as well as in 
vitro and in vivo competition studies will be published) and Lu- 
derschmidt et al [8]. Th e same group demonstrated the topical effec- 
tiveness of PM and the missing systemic effects of this antiandrogen 
[21]. PRO, on the other hand, showed a very slight sebosuppressive 
effect when applied topically in humans. The effect was confined to 
females [I]. 
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